Journal profile · CARDIAC & CARDIOVASCULAR SYSTEMS
Cardiovascular Endocrinology & Metabolism
ISSN 2574-0954 · Wolters Kluwer Health · United States
Cardiovascular Endocrinology & Metabolism: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.4 (journal website); JCR Q3 (journal website); fully open access; APC about USD 1,200; median 87 days to acceptance (39 articles, last 24 months); 22 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Cardiovascular Endocrinology & Metabolism is published by Wolters Kluwer Health and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Diabetes Treatment and Management, Cardiovascular Function and Risk Factors and Diabetes Management and Research, together about 30.7% of its articles. Its main subfields are Endocrinology, Diabetes and Metabolism. (generated from OpenAlex topic counts and CAS ranking data)
Cardiovascular Endocrinology & Metabolism is an open access journal, owned and published by Wolters Kluwer, and dedicated to supporting cardiovascular and diabetes patient care, research and education. Cardiovascular Endocrinology & Metabolism publishes peer-reviewed research in vascular disease, endocrinology, diabetes and metabolism. Particular emphasis is placed on studies that illuminate the interaction between these disciplines and foster effective collaboration between cardiologists, endocrinologists and diabetologists. The journal serves as a single resource for research and clinical communities specialising in cardiology, endocrinology, diabetology, and metabolism. High quality state-of-the-art reviews, invited editorials, and expert commentaries place original articles in context at the interface of basic and clinical research.
From the journal's Aims & Scope
Research area (LetPub): CARDIAC & CARDIOVASCULAR SYSTEMS
Editor-in-chief Andrew J. KrentzPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Diabetes Treatment and ManagementMedicine12.9%
- Cardiovascular Function and Risk FactorsMedicine9.9%
- Diabetes Management and ResearchMedicine7.9%
- Diabetes, Cardiovascular Risks, and LipoproteinsMedicine7.3%
- Adipokines, Inflammation, and Metabolic DiseasesMedicine4.6%
- COVID-19 Clinical Research StudiesMedicine4.3%
- Hyperglycemia and glycemic control in critically ill and hospitalized patientsMedicine4.3%
- Lipoproteins and Cardiovascular HealthMedicine4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Cardiac & Cardiovascular Systems | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Cardiac & Cardiovascular Systems | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
JCR / CiteScore quartiles on the journal's website
- JCR Q3 · CARDIAC & CARDIOVASCULAR SYSTEMS · rank 172/237
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 1.4Publisher website ·
- CiteScore 2026-06
- 1.7LetPub ·
- SJR 2026-06
- 0.51LetPub ·
- SNIP 2026-06
- 0.34LetPub ·
- h-index
- 23OpenAlex ·
- i10-index
- 51OpenAlex ·
- 2-year mean citedness
- 3.29OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 95.38%LetPub ·
Volume
- Articles per year
- 27LetPub ·
Articles by year OpenAlex count · 214 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 2 | 2 | 0 |
| 2025 | 22 | 22 | 47 |
| 2024 | 25 | 25 | 114 |
| 2023 | 18 | 18 | 90 |
| 2022 | 20 | 20 | 68 |
| 2021 | 14 | 14 | 140 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
87 daysMedian, submission to acceptance · P25–P75 51 days – 130 days
- Acceptance to online
- median 27 days (39 articles)
- Submission to online
- median 118 days
- Sample
- 39 articles with submission and acceptance dates (46 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 15 weeksLetPub ·
- Submission to publication (journal-reported)
- about 15 weeksDOAJ ·
- Peer review
- Double anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 1,200 | No | CC BY, CC BY-SA, CC BY-ND, CC BY-NC, CC BY-NC-SA, CC BY-NC-ND | |
| Publisher website | USD 1,600 / USD 800 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted7, with length limits
- editorialwing types of articles for publication. Editorials Editorials should deal with topical subjects and should not be longer than 2000 words including references. F…main text ≤ 2,000 words
- editorialsEditorials should deal with topical subjects and should not be longer than 2000 words including references.Length not stated
- mini-reviewsMini-reviews are generally commissioned but non-commissioned mini-reviews are welcome. They should be no more than 2,000 words in length and include an unstruct…Length not stated
- original articlesOriginal articles require a structured abstract of no more tLength not stated
- revieware not usually included in editorials. Reviews Review papers should be no more than 4000 words in length and include no more than a total of 4 tables and/main text ≤ 4,000 words
- reviewsReview papers should be no more than 4000 words in length and include no more than a total of 4 tables and/or figures and no more than 150 references.Length not stated
- viewpointhe Editor-in-Chief prior to submission. Viewpoints should be limited to 1500 words, include a short unstructured abstract, and can have up tomain text ≤ 1,500 words
Policy excerpts from the journal's websiteAI use, Conflicts of interest, Open access, Peer review, Plagiarism
- AI use Artificial Intelligence (AI) and AI-assisted technologies
The journal does not consider Artificial Intelligence (AI) authoring tools to meet the requirements for Authorship as recommended by the ICMJE. Authors who use AI tools in the writing of a manuscript, production of images or graphical elements of the paper, or in the collection and analysis of data, must be transparent in disclosing in the Materials and Methods (or similar section) of the paper ho…
Source ↗Publisher website ·- Conflicts of interest
Conflicts of interest must be stated Model summary
Authors must state all possible conflicts of interest in the manuscript, including financial, consultant, institutional and other relationships that might lead to bias or a conflict of interest. If there is no conflict of interest, this should also be explicitly stated as none declared.
Source ↗Publisher website ·- Open access
Research4Life waivers for low/middle-income economies Model summary
Cardiovascular Endocrinology & Metabolism offers full or partial equitable waivers for accepted articles from low-income and middle-income economies. Eligibility is based on the Research4Life eligibility criteria.
Source ↗Publisher website ·- Peer review
Double-blind peer review Model summary
All articles submitted to Cardiovascular Endocrinology & Metabolism are subject to critical double-blind peer review by our editors and by external experts in the fields of cardiology, diabetes and endocrinology.
Source ↗Publisher website ·- Plagiarism
Plagiarism detection software may be used Model summary
The Editorial team may subject any manuscript submitted for consideration of publication in the Journal to plagiarism- detection software.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Wolters Kluwer Health
- Country or region
- United States
- Language
- English
- ISSN
- 2574-0954
- Latest issue on the website
- Volume 15, Issue 3 (September 2026)
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- APC information ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Cardiovascular Endocrinology & Metabolism
What CAS zone is Cardiovascular Endocrinology & Metabolism in?
In the 2025 upgraded edition of the CAS Journal Ranking, Cardiovascular Endocrinology & Metabolism is in Zone 4 of Medicine, and in Zone 4 of the minor category Cardiac & Cardiovascular Systems. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cardiovascular Endocrinology & Metabolism?
The journal's website gives an impact factor of 1.4; this is the journal's own figure, as LetPub lists none for it; CiteScore 1.7, h-index 23.
How long does peer review take at Cardiovascular Endocrinology & Metabolism?
Based on the dates recorded on 39 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 87 days (interquartile range 51–130 days); authors report an average review time of about 15 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Cardiovascular Endocrinology & Metabolism in?
The journal's website gives JCR Q3; by category, CARDIAC & CARDIOVASCULAR SYSTEMS Q3 (172/237). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 4 of Medicine.
Which databases index Cardiovascular Endocrinology & Metabolism?
According to LetPub and DOAJ records, Cardiovascular Endocrinology & Metabolism is indexed in ESCI, Scopus and DOAJ.
Is Cardiovascular Endocrinology & Metabolism open access, and what is the APC?
Cardiovascular Endocrinology & Metabolism is a fully open-access journal. APC about USD 1,200.
Sources and updates
The facts on this page come from LetPub, DOAJ, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .